S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
As Musk is learning, content moderation is a messy job
"The Bull Market Is Officially OVER"  (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
As Musk is learning, content moderation is a messy job
"The Bull Market Is Officially OVER"  (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
As Musk is learning, content moderation is a messy job
"The Bull Market Is Officially OVER"  (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
As Musk is learning, content moderation is a messy job
"The Bull Market Is Officially OVER"  (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
FDA change ushers in cheaper, easier-to-get hearing aids
NASDAQ:ISEE

IVERIC bio - ISEE Stock Forecast, Price & News

$23.06
+0.30 (+1.32%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$22.08
$23.15
50-Day Range
$14.82
$23.95
52-Week Range
$8.85
$24.33
Volume
4.91 million shs
Average Volume
3.42 million shs
Market Capitalization
$2.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.20

IVERIC bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
13.6% Upside
$26.20 Price Target
Short Interest
Healthy
6.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of IVERIC bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.89 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.44) to ($1.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

625th out of 1,034 stocks

Pharmaceutical Preparations Industry

300th out of 502 stocks

ISEE stock logo

About IVERIC bio (NASDAQ:ISEE) Stock

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Stock News Headlines

IVERIC bio (NASDAQ:ISEE) Trading Up 3.6%
IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
IVERIC bio: Q3 Earnings Insights
IVERIC bio's Earnings: A Preview
IVERIC bio Whale Trades For October 05
Why Iveric Bio Stock Is Skyrocketing This Week
Analyst Ratings for IVERIC bio
Iveric Bio to Present at Upcoming Investor Conferences
This Is What Whales Are Betting On IVERIC bio
See More Headlines
Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Company Calendar

Last Earnings
11/08/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISEE
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.20
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+13.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-114,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.15 per share

Miscellaneous

Free Float
117,463,000
Market Cap
$2.78 billion
Optionable
Optionable
Beta
1.01

Key Executives

  • Mr. Glenn P. Sblendorio M.B.A.Mr. Glenn P. Sblendorio M.B.A. (Age 66)
    CEO & Director
    Comp: $1.3M
  • Dr. Pravin U. Dugel M.D. (Age 58)
    Pres
    Comp: $926.9k
  • Mr. David F. Carroll M.B.A. (Age 56)
    Sr. VP, CFO & Treasurer
    Comp: $713.65k
  • Mr. Christopher Paul SimmsMr. Christopher Paul Simms (Age 47)
    Sr. VP & Chief Commercial Officer
    Comp: $668.25k
  • Mr. Anthony S. Gibney (Age 51)
    Exec. VP and Chief Bus. & Strategy Officer
    Comp: $1.5M
  • Dr. Samir C. Patel (Age 61)
    Co-Founder and Consultant
  • Mr. Keith Westby M.B.A.Mr. Keith Westby M.B.A. (Age 47)
    Sr. VP & COO
  • Dr. Xiao-Ping Dai Ph.D.
    Chief Technical Officer
  • Ms. Kathy Galante
    Sr. VP of Investor Relations & Corp. Communications
  • Mr. Todd D.C. Anderman
    Sr. VP, Gen. Counsel & Corp. Sec.













ISEE Stock - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ISEE shares.
View ISEE analyst ratings
or view top-rated stocks.

What is IVERIC bio's stock price forecast for 2023?

9 analysts have issued 12-month target prices for IVERIC bio's stock. Their ISEE share price forecasts range from $8.00 to $35.00. On average, they anticipate the company's share price to reach $26.20 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price.
View analysts price targets for ISEE
or view top-rated stocks among Wall Street analysts.

How have ISEE shares performed in 2022?

IVERIC bio's stock was trading at $16.72 at the beginning of the year. Since then, ISEE shares have increased by 37.9% and is now trading at $23.06.
View the best growth stocks for 2022 here
.

Are investors shorting IVERIC bio?

IVERIC bio saw a decline in short interest in November. As of November 15th, there was short interest totaling 8,170,000 shares, a decline of 9.2% from the October 31st total of 9,000,000 shares. Based on an average trading volume of 6,360,000 shares, the short-interest ratio is currently 1.3 days.
View IVERIC bio's Short Interest
.

When is IVERIC bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ISEE earnings forecast
.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.06. During the same quarter last year, the firm earned ($0.27) EPS.

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.73%), State Street Corp (5.17%), Vanguard Group Inc. (5.07%), TCG Crossover Management LLC (3.21%), RTW Investments LP (3.00%) and Price T Rowe Associates Inc. MD (2.85%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends
.

How do I buy shares of IVERIC bio?

Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $23.06.

How much money does IVERIC bio make?

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $2.78 billion. The company earns $-114,520,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (212) 845-8200 or via email at kathy.galante@ivericbio.com.

This page (NASDAQ:ISEE) was last updated on 12/4/2022 by MarketBeat.com Staff